182 related articles for article (PubMed ID: 22721797)
41. [The digital rectal exam, prostate-specific antigen and transrectal echography in the diagnosis of prostatic cancer].
Martínez de Hurtado J; Chéchile Toniolo G; Villavicencio Mavrich H
Arch Esp Urol; 1995 Apr; 48(3):247-59. PubMed ID: 7538749
[TBL] [Abstract][Full Text] [Related]
42. Prostate cancer in the elderly.
Konstantinos H
Int Urol Nephrol; 2005; 37(4):797-806. PubMed ID: 16362603
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis, management and screening of early localised prostate cancer.
Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
[TBL] [Abstract][Full Text] [Related]
44. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
45. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
[TBL] [Abstract][Full Text] [Related]
46. [Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel].
Thomas C; Bögemann M; König F; Machtens S; Schostak M; Steuber T; Heidenreich A
Urologe A; 2016 Jun; 55(6):772-82. PubMed ID: 26820660
[TBL] [Abstract][Full Text] [Related]
47. The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer.
Abern MR; Terris MK; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
Cancer; 2014 Jun; 120(11):1656-62. PubMed ID: 24647966
[TBL] [Abstract][Full Text] [Related]
48. Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database.
Flaig TW; Potluri RC; Ng Y; Todd MB; Mehra M; Higano CS
Clin Genitourin Cancer; 2017 Apr; 15(2):273-279.e1. PubMed ID: 27876504
[TBL] [Abstract][Full Text] [Related]
49. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
50. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
Postma R; Roobol M; Schröder FH; van der Kwast TH
Cancer; 2004 Mar; 100(5):968-75. PubMed ID: 14983492
[TBL] [Abstract][Full Text] [Related]
51. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
52. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].
Heidenreich A; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Mottet N; Schmid HP; van der Kwast T; Wiegel T; Zattoni F
Actas Urol Esp; 2011 Oct; 35(9):501-14. PubMed ID: 21757259
[TBL] [Abstract][Full Text] [Related]
53. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
Feneley MR; Gillatt DA; Hehir M; Kirby RS
Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
[TBL] [Abstract][Full Text] [Related]
54. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
[TBL] [Abstract][Full Text] [Related]
56. [Androgen deprivation for advanced prostate cancer].
Heidenreich A; Pfister D; Ohlmann CH; Engelmann UH
Urologe A; 2008 Mar; 47(3):270-83. PubMed ID: 18273599
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic options for advanced prostate cancer: 2011 update.
Omlin A; de Bono JS
Curr Urol Rep; 2012 Apr; 13(2):170-8. PubMed ID: 22373838
[TBL] [Abstract][Full Text] [Related]
58. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
Cassinello J; Arranz JÁ; Piulats JM; Sánchez A; Pérez-Valderrama B; Mellado B; Climent MÁ; Olmos D; Carles J; Lázaro M
Clin Transl Oncol; 2018 Jan; 20(1):57-68. PubMed ID: 29134562
[TBL] [Abstract][Full Text] [Related]
59. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy.
D'Amico AV; Renshaw AA; Arsenault L; Schultz D; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):841-6. PubMed ID: 10571187
[TBL] [Abstract][Full Text] [Related]
60. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
